Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
Viruses · 2023
DOI: 10.3390/v15081702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Martina Gambato und 12 weiteren Autor:innen. Beteiligte Einrichtung: Multivisceral Transplant and Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale-Università Padova, Via Giu…. Hauptthemen laut MEDLINE: Hepatitis C, Liver Transplantation, Antiviral Agents, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Little is known about the long-term impact of sustained virological response (SVR) on fibrosis progression and patient survival in liver transplantation (LT) recipients treated with direct-acting antivirals (DAAs). We investigated liver fibrosis evolution and patient survival in hepatitis C virus (HCV)-infected patients receiving DAAs after LT. (2)
Methods
All consecutive HCV-infected patients treated with DAAs after LT between May 2014 and January 2019 were considered. The clinical and virological features were registered at the baseline and during the follow-up. The liver fibrosis was assessed by liver biopsy and/or transient elastography (TE) at the baseline and at least 1 year after the end of treatment (EoT). (3)
Results
A total of 136 patients were included. The SVR12 was 78% after the first treatment and 96% after retreatment. After the SVR12, biochemical tests improved at the EoT and remained stable throughout the 3-year follow-up. Liver fibrosis improved after the SVR12 (p < 0.001); nearly half of the patients with advanced liver fibrosis experienced an improvement of an F ≤ 2. The factors associated with lower survival in SVR12 patients were the baseline platelet count (p = 0.04) and creatinine level (p = 0.04). (4)
Conclusions
The long-term follow-up data demonstrated that SVR12 was associated with an improvement in hepatic function, liver fibrosis, and post-LT survival, regardless of the baseline liver fibrosis. The presence of portal hypertension before the DAAs has an impact on patient survival, even after SVR12.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multivisceral Transplant and Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale-Università Padova, Via Giustiniani 2, 35100 Padova, Italy.
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35100 Padova, Italy.
- Hepatobiliary Urgery and Liver Transplantation, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale-Università Padova, 35100 Padova, Italy.
ORCID-Profile: Martina Gambato, Erica N Lynch, Alberto Zanetto, Alessandro Vitale, Enrico Gringeri, Patrizia Burra, Francesco Paolo Russo
Zitieren
APA
Gambato, M., Manuli, C., Lynch, E. N., Battistella, S., Germani, G., Senzolo, M., Zanetto, A., Ferrarese, A., Vitale, A., Gringeri, E., Cillo, U., Burra, P., & Russo, F. P. (2023). Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients. Viruses. https://doi.org/10.3390/v15081702
Vancouver
Gambato M, Manuli C, Lynch EN, Battistella S, Germani G, Senzolo M, et al. Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients. Viruses. 2023. doi:10.3390/v15081702
BibTeX
@article{Gambato2023,
author = {Gambato, Martina and Manuli, Chiara and Lynch, Erica N and Battistella, Sara and Germani, Giacomo and Senzolo, Marco and Zanetto, Alberto and Ferrarese, Alberto and Vitale, Alessandro and Gringeri, Enrico and Cillo, Umberto and Burra, Patrizia and Russo, Francesco Paolo},
title = {Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15081702}
}
EUVIMED